Agentix Biopharma is a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. GPCRs are considered the largest family of proven therapeutic targets. To date there are over 134 drugs approved in the United States or the European Union which target GPCRs generating several billion dollars annually in revenues for pharmaceutical companies.[1]

Agentix Biopharma has developed partnerships with leading academic and research institutions. Agentix Biopharma has exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. Agentix Biopharma is advancing these therapeutic product candidates in clinical trials.